Current Therapeutic Approach in Non-infectious Uveitis

1. Cyclosporin a for posterior uveitis? JAMA, 1982; 247: 569.

2. Accorinti, M., Pirraglia, M.P., Paroli, M.P., et al.: Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Jpn J Ophthalmol, 2007; 51: 191–196.

3. Agarwal, R.K., Caspi, R.R.: Rodent models of experimental autoimmune uveitis. Methods Mol Med, 2004; 102: 395–419.

4. Agarwal, R.K., Kang, Y., Zambidis, E., et al.: Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest, 2000; 106: 245–252.

5. Androudi, S., Letko, E., Meniconi, M., et al.: Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm, 2005; 13: 205–212.

6. Biester, S., Deuter, C., Michels, H., et al.: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol, 2007; 91: 319–324.

7. Bodaghi, B., Gendron, G., Wechsler, B., et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol, 2007; 91: 335–339.

8. Caspi, R.R., Grubbs, B.G., Chan, C.C., et al.: Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol, 1992; 148: 2384–2389.

9. Cunningham, M.A., Austin, B.A., Li, Z., et al.: LX211 (voclosporin) suppresses experimental uveitis and inhibits human T-cells. Invest Ophthalmol Vis Sci, 2008; [e-pub ahead of print].

10. Cunningham, M.A., Edelman, J.L. Kaushal, S.: Intravitreal steroids for macular edema: The past, the present, and the future. Surv Ophthalmol, 2008; 53: 139–149.

11. Diaz-Llopis, M., Garcia-Delpech, S., Salom, D., et al.: Adalimumab therapy for refractory uveitis: A pilot study. J Ocul Pharmacol Ther, 2008; 24: 351–361.

12. Foeldvari, I., Nielsen, S., Kummerle-Deschner, J., et al.: Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: Results of a multinational survey. J Rheumatol, 2007; 34: 1146–1150.

13. Greiner, K., Plšková, J.: [TNFalpha inhibitors in the treatment of uveitis]. Ophthalmologe, 2005; 102: 335–340.

14. Helm, C.J., Holland, G.N.: The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol, 1995; 120: 55–64.

15. Choudhry, S., Ghosh, S.: Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema. Clin Experiment Ophthalmol, 2007; 35: 713–718.

16. Imrie, F.R., Dick, A.D.: Biologics in the treatment of uveitis. Curr Opin Ophthalmol, 2007; 18: 481–486.

17. Kahn, P., Weiss, M., Imundo, L.F., et al.: Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology, 2006; 113: 860-864 e2, [e-pub ahead of print].

18. Kok, H., Lau, C., Maycock, N., et al.: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology, 2005; 112: 1916 e11–17 [e-pub ahead of print].

19. Kotter, I., Eckstein, A.K., Stubiger, N., et al.: Treatment of ocular symptoms of Behcet’s disease with interferon alpha 2a: A pilot study. Br J Ophthalmol, 1998; 82: 488–494.

20. Lamprecht, P., Arbach, O., Voswinkel, J., et al.: [Induction of remission with infliximab in therapy-refractory Wegener’s granulomatosis - follow-up of six patients]. Dtsch Med Wochenschr, 2002; 127: 1876–1880.

21. Lamprecht, P., Voswinkel, J., Lilienthal, T., et al.: Effectiveness of tnf-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford), 2002; 41: 1303–1307.

22. Mangge, H., Heinzl, B., Grubbauer, H.M., et al.: Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int, 2003; 23: 258–261.

23. Mattapallil, M.J., Sahin, A., Silver, P.B., et al.: Common genetic determinants of uveitis shared with other autoimmune disorders. J Immunol, 2008; 180: 6751–6759.

24. Mohammad, D.A., Sweet, B.V. Elner, S.G.: Retisert: Is the new advance in treatment of uveitis a good one? Ann Pharmacother, 2007; 41: 449-454.

25. Murphy, C.C., Greiner, K., Plšková, J., et al.: Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol, 2005; 123: 634–641.

26. Mushtaq, B., Saeed, T., Situnayake, R.D., et al.: Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye, 2007; 21: 824–825.

27. Niccoli, L., Nannini, C., Benucci, M., et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: A 24-month follow-up study. Rheumatology (Oxford), 2007; 46: 1161–1164.

28. Nussenblatt, R.B., Peterson, J.S., Foster, C.S., et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: A multicenter noncomparative interventional case series. Ophthalmology, 2005; 112: 764–770.

29. Plšková, J., Greiner, K., Forrester, J.V.: Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol, 2007; 144: 55–61.

30. Poch, T., Říhová, E., Michalová, K.: Imunologické mechanismy a jejich ovlivnění imunosupresívní terapií v očním lékařství. Čes Oftalmol, 1993; 49: 131–138.

31. Rosenzweig, H.L., Martin, T.M., Jann, M.M., et al.: NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. Invest Ophthalmol Vis Sci, 2008; 49: 1518–1524.

32. Rothova, A., Suttorp-van Schulten, M.S., Frits Treffers, W., et al.: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol, 1996; 80: 332–336.

33. Rudometkin, N., Mandava, N., Deane, K., et al.: Infliximab in uveitis treatment. Arch Ophthalmol, 2006; 124: 1211; author reply 1211–1212.

34. Rudwaleit, M., Rodevand, E., Holck, P., et al.: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis, 2008; [e-pub ahead of print].

35. Říhová, E., Boguszaková, J., Michalová, K., et al.: Naše zkušenosti s imunosupresívní léčbou endogenní uveitidy. Čes Oftalmol, 1993; 49: 139–144.

36. Říhová, E., Poch, T., Boguszaková, J., et al.: První zkušenosti s terapií endogenní uveitidy Consuprenem – českým cyklosporinem A. Čes Oftalmol, 1994; 50: 302–309.

37. Siepmann, K., Huber, M., Stubiger, N., et al.: Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : A retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol, 2006; 244: 788–794.

38. Sobrin, L., Kim, E.C., Christen, W., et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol, 2007; 125: 895–900.

39. Suttorp-Schulten, M.S., Rothova, A.: The possible impact of uveitis in blindness: A literature survey. Br J Ophthalmol, 1996; 80: 844–848.

40. Svozílková, P., Říhová, E., Brichová, M., et al.: Infliximab v léčbě Wegenerovy granulomatózy: kazuistika. Česk Slov Oftalmol, 2006; 62: 280–286.

41. Teoh, S.C., Hogan, A.C., Dick, A.D., et al.: Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol, 2008; [e-pub ahead of print].

42. Tynjala, P., Kotaniemi, K., Lindahl, P., et al.: Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford), 2008; 47: 339–344.

43. Tynjala, P., Lindahl, P., Honkanen, V., et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis, 2007; 66: 548–550.

44. Venkatesh, P., Garg, S.P., Verma, L., et al.: Posterior subtenon injection of corticosteroids using polytetrafluoroethylene (PTFE) intravenous cannula. Clin Experiment Ophthalmol, 2002; 30: 55–57.

45. Wormald, R., Evans, J.: Needs and demands for ophthalmology services. BMJ, 1992; 305: 1502.

46. Wormald, R.P., Wright, L.A., Courtney, P., et al.: Visual problems in the elderly population and implications for services. BMJ, 1992; 304: 1226–1229.

47. Xu, H., Wawrousek, E.F., Redmond, T.M., et al.: Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis. Eur J Immunol, 2000; 30: 272–278.

48. Yadav, U.C., Srivastava, S.K. Ramana, K.V.: Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci, 2007; 48: 4634–4642.

49. Yeh, S., Wroblewski, K., Buggage, R., et al.: High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun, 2008; 31: 91–97.

50. Young, S., Larkin, G., Branley, M., et al.: Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol, 2001; 29: 2–6.

51. Zierhut, M., Stubiger, N., Aboalchamat, W., et al.: [Immunosuppressive therapy with mycophenolate mofetil (Cellcept) in treatment of uveitis]. Ophthalmologe, 2001; 98: 647–651.